phendimetrazine extended release / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   0 Trials   0 Trials   36 News 
  • ||||||||||  FDA event, Journal:  Comparison table: Some FDA-approved drugs for weight management. (Pubmed Central) -  Jun 11, 2022   
    The relative potential of drug-induced reward-seeking behavior may be related to DAT availability-mediated extracellular dopamine levels in the mPFC and NAc. No abstract available
  • ||||||||||  Bontril (phendimetrazine extended release) / Bausch Health
    Clinical, Journal:  Effect of JumpstartMD, a Commercial Low-Calorie Low-Carbohydrate Physician-Supervised Weight Loss Program, on 22,407 Adults. (Pubmed Central) -  May 20, 2021   
    JumpstartMD produced generally greater weight loss than published reports for other real-food and prepackaged-meal commercial programs and somewhat greater or comparable losses to meal replacement diets. A one-on-one medically supervised program that emphasized real low-carbohydrate foods produced effective weight loss, particularly in those attending ≥75% of their weekly appointments.
  • ||||||||||  methylphenidate tablet / Generic mfg.
    Clinical, Journal:  Evaluation of pharmaceutical abuse and illicit drug use in South Korea by wastewater-based epidemiology. (Pubmed Central) -  Apr 27, 2021   
    The mean estimated meperidine and cis-tramadol (opioid) consumption rates were 120 and 27.5 mg d (1000 people), respectively, and were 8.2 and 1.7 times higher, respectively, than the consumption rates found in 2013. Methylphenidate was detected in the influent and effluent samples at mean concentrations of 2.7 and 2.6 ng L, respectively, but the methylphenidate consumption rate could not be estimated because of the low excretion rate for humans (<1%).
  • ||||||||||  TRENDS OF SLEEVE GASTRECTOMY AND POST-OPERATIVE WEIGHT LOSS PHARMACOTHERAPY OVER 10 YEARS: A LARGE DATABASE STUDY (S105bc) -  May 19, 2020 - Abstract #SSAT2020SSAT_294;    
    We studied the individuals who were prescribed at least one weight loss medication [orlistat, liraglutide (Saxenda), lorcaserin, phentermine-topiramate, bupropion-naltrexone, phentermine, diethylpropion, benzphetamine, and phendimetrazine] at least 7 days after the procedure...Despite the growing trend, sleeve gastrectomy and post-operative anti-obesity pharmacotherapy are underutilized in the US with < 1% of obese adults undergoing SG out of which < 5% being prescribed anti-obesity pharmacotherapy. Further large-scale studies are required to explore interventions to increase the utilization of these therapies.
  • ||||||||||  PHARMACOTHERAPY FOR OBESITY – TRENDS USING A POPULATION LEVEL NATIONAL DATABASE () -  May 4, 2020 - Abstract #DDW2020DDW_5829;    
    Short-term agents ( 5 years ago, only a small fraction of obese adults have been prescribed these drugs. Further studies are required to explore the barriers involved in the prescription of these medications and other reasons for their slow implementation.
  • ||||||||||  TRENDS OF SLEEVE GASTRECTOMY AND POST-OPERATIVE WEIGHT LOSS PHARMACOTHERAPY OVER 10 YEARS: A LARGE DATABASE STUDY () -  May 4, 2020 - Abstract #DDW2020DDW_4094;    
    We studied the individuals who were prescribed at least one weight loss medication [orlistat, liraglutide (Saxenda), lorcaserin, phentermine-topiramate, bupropion-naltrexone, phentermine, diethylpropion, benzphetamine, and phendimetrazine] at least 7 days after the procedure...Despite the growing trend, sleeve gastrectomy and post-operative anti-obesity pharmacotherapy are underutilized in the US with < 1% of obese adults undergoing SG out of which < 5% being prescribed anti-obesity pharmacotherapy. Further large-scale studies are required to explore interventions to increase the utilization of these therapies.
  • ||||||||||  Bontril (phendimetrazine extended release) / Bausch Health
    Trial completion:  BED IN 31: Reinforcing Effects of Cocaine During Phendimetrazine Maintenance (clinicaltrials.gov) -  Jan 16, 2019   
    P1,  N=29, Completed, 
    It is unlikely, then, that phendimetrazine will be an effective standalone treatment for cocaine use disorder. Recruiting --> Completed
  • ||||||||||  Journal:  Pharmacological management of obesity. (Pubmed Central) -  Nov 28, 2018   
    Medications for obesity can be simply categorized as FDA approved short-term use (diethylproprion, phendimetrazine, benzphetamine, and phentermine) and long-term use (orlistat, phentermine/topiramate ER, lorcaserin, naltrexone/bupropion ER and liraglutide)...Finally, weight-centric prescribing is also an important component to pharmacological management of obesity. It warrants that healthcare providers thoroughly review their patients' medication lists to determine if any of these agents could be contributing to weight gain.
  • ||||||||||  Bontril (phendimetrazine extended release) / Bausch Health
    Trial primary completion date:  BED IN 31: Reinforcing Effects of Cocaine During Phendimetrazine Maintenance (clinicaltrials.gov) -  Apr 6, 2017   
    P1,  N=36, Recruiting, 
    It warrants that healthcare providers thoroughly review their patients' medication lists to determine if any of these agents could be contributing to weight gain. Trial primary completion date: Jul 2018 --> Nov 2018
  • ||||||||||  phendimetrazine extended release / Generic mfg.
    Trial completion, Trial primary completion date:  Phendimetrazine and Cocaine (clinicaltrials.gov) -  May 11, 2016   
    P0,  N=10, Completed, 
    Trial primary completion date: Jul 2018 --> Nov 2018 Recruiting --> Completed | Trial primary completion date: May 2016 --> Dec 2015
  • ||||||||||  Bontril (phendimetrazine extended release) / Bausch Health
    Clinical:  Phendimetrazine and Cocaine (clinicaltrials.gov) -  Sep 8, 2014   
    P0,  N=12, Recruiting,